We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

By LabMedica International staff writers
Posted on 03 Apr 2025

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch, Germany), a global leader in anatomic pathology solutions. More...

This expansion builds on the strong partnership between Bio-Techne and Leica Biosystems, established in 2015, to deliver automated in-situ hybridization (ISH) workflows that streamline spatial biology research. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spatial biology research.

The RNAscope Multiomic LS Assay enables simultaneous fluorescent detection of up to six RNA and/or protein biomarkers on the same slide, preserving RNA and protein integrity while maintaining tissue morphology. Additionally, ACD introduced a protease-free workflow for RNAscope 2.5 single-plex assays on the Leica BOND RX staining instrument, further advancing multiomic visualization from discovery research to translational applications. The RNAscope in situ spatial assays have been widely adopted by top academic institutions, pharmaceutical companies, and service providers worldwide, contributing to over 12,000 peer-reviewed publications.

"The automation of Bio-Techne's innovative RNAscope protease-free assays on the Leica BOND RX platform marks a significant milestone in spatial multiomics research," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "High-precision visualization of RNA and protein biomarkers on the same slide empowers researchers with a streamlined, fully automated solution that preserves sample integrity and accelerates scientific discoveries in translational and clinical research."

"At Leica Biosystems, we are committed to empowering researchers with innovative automation solutions that accelerate spatial biology discovery," said Karan Arora, Senior Vice President of Advanced Assays at Leica Biosystems. "The integration of ACD's RNAscope Multiomic LS Assay on the BOND RX reinforces our mission to provide cutting-edge tools that enhance precision and scalability in life science research."

Related Links:
Bio-Techne Corporation
ACD
Leica Biosystems


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.